ATX-201

ATX-201 is a preclinical-stage drug candidate being developed by Allay Therapeutics for the management of post-operative pain. It is part of a new category of ultra-sustained therapeutics built on Allay's proprietary drug-biopolymer platform technology. This platform combines validated non-opioid local anesthetics with biopolymers to enable localized, extended-release delivery of analgesic agents directly to the surgical site. By providing sustained pain relief over an extended period, ATX-201 aims to improve post-surgical recovery and reduce the clinical reliance on systemic opioids. As a "new formulation" extension of Allay's platform, it represents a strategic expansion of their localized pain management pipeline.